Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tislelizumab + etoposide
- Development stage
- Unknown
- Lead developer
- BeOne Medicines
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
Tislelizumab + etoposide is a combination regimen consisting of tislelizumab, a humanized IgG4 monoclonal antibody targeting programmed cell death protein 1 (PD-1), and etoposide, a small-molecule topoisomerase II inhibitor. Developed by BeiGene (now BeOne Medicines), this combination is typically administered intravenously in conjunction with a platinum agent (cisplatin or carboplatin) for the first-line treatment of extensive-stage small cell lung cancer (ES-SCLC). In the phase 3 RATIONALE-312 trial, the addition of tislelizumab to etoposide and platinum chemotherapy demonstrated a statistically significant and clinically meaningful improvement in overall survival compared to placebo plus chemotherapy. The combination has been approved by China's National Medical Products Administration (NMPA) and recommended by the European Medicines Agency's CHMP for first-line ES-SCLC, and is also being investigated in phase 2 trials for limited-stage small cell lung cancer (LS-SCLC).
- Other names
- BGB-A317 + etoposidetislelizumab plus etoposide
02
Targets
TOP2A (DNA topoisomerase II)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on tislelizumab + etoposide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tislelizumab + etoposide.